Lipidil One

Fenofibrate, the active ingredient in Lipidil One, is a fibrate presented as a tablet for oral use. It lowers elevated triglyceride and cholesterol levels in adults with dyslipidemia.

GNH USA supplies Lipidil One as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Fenofibrate acts on lipid metabolism disorders, helping to improve abnormal blood‑fat profiles.

Hypertriglyceridemia: reduces serum triglyceride concentrations. Mixed dyslipidemia: lowers triglycerides and LDL‑cholesterol while modestly raising HDL‑cholesterol. Primary hypercholesterolemia: decreases total and LDL‑cholesterol levels.

Fenofibrate may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Abdominal discomfort or dyspepsia. - Nausea or vomiting. - Headache. - Dizziness. - Muscle pain or weakness. - Elevated liver enzymes.

Serious or Rare Side Effects: - Rhabdomyolysis or severe myopathy. - Acute liver injury. - Gallstone formation. - Severe allergic reactions (e.g., Stevens‑Johnson syndrome). - Pancreatitis. - Significant increase in serum creatinine.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor relevant parameters.

Assess liver function: obtain baseline hepatic enzymes and repeat periodically. Monitor renal function: adjust use in patients with impaired clearance. Evaluate muscle health: watch for unexplained muscle pain or weakness. Review concomitant drugs: avoid or adjust agents that increase myopathy risk. Avoid in patients with known hypersensitivity to fenofibrate or other fibrates. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Fenofibrate can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Statins, especially high‑dose simvastatin or atorvastatin, due to increased myopathy risk. - Gemfibrozil, which markedly raises fenofibrate plasma levels. - Cyclosporine, which can exacerbate hepatic toxicity.

Moderate Interactions (Monitor Closely): - Bile‑acid sequestrants, which may reduce fenofibrate absorption. - Digoxin, where fenofibrate may increase serum concentrations. - Oral contraceptives, potentially altering hormone levels. - Antidiabetic agents, requiring glucose monitoring.